We reiterate our Outperform rating for Cerner Corporation (CERN). Its first quarter earnings of $0.51 a share beat the Zacks Consensus Estimate. Cerner remains the trend setter among pure-play, publicly-traded healthcare IT (HCIT) vendors.
We believe Cerner is one of the better placed clinical technology vendors to benefit from high HCIT spending over the next few years. The company is diversified not only on a global basis but serves both hospitals and ambulatory outfits. Its integrated solutions have captured market share.
Long-term investors may consider Cerner, which serves a sizeable installed hospital base that requires composite clinically-focused applications complying with meaningful use requirements, reimbursement problems and complex coding challenges.
CERNER CORP (CERN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research